Purpose: This study contributes to the characterization of primary colorectal signet-ring cell cancer in contrast to ordinary colorectal carcinoma. Primary colorectal signet-ring cell cancer is a rare but distinctive primary neoplasm of the large bowel with still-controversial clinicopathologic features.

Methods: Clinicopathologic features and survival data are evaluated in comparison with those of the ordinary colorectal adenocarcinoma (non-signet colorectal carcinoma) in a retrospective study matched for age, gender, grade, and stage.

Results: In a series of 1,600 consecutive colorectal cancer patients since 1979, 14 patients (0.88 percent) with a signet-ring cell cancer were identified. Gender ratio was balanced, and mean age was 67.5 years. The majority of patients had an advanced tumor stage at the time of diagnosis (57.1 percent Stage IV and 35.7 percent Stage III). Median survival time was only 16 months. In a study matched for age, gender, grade, and stage, a lower survival rate was found for patients with signet-ring cell cancer, but the difference did not reach statistical significance. In contrast to non-signet colorectal carcinoma, signet-ring cell cancer was characterized by a significantly higher incidence of peritoneal tumor spread (64.3 percent) and a lower incidence of hepatic metastases (14.3 percent).

Conclusions: Signet-ring cell cancer represents a rare but distinctive primary neoplasm of the large bowel. It is frequently diagnosed in an advanced tumor stage, thus showing an overall poorer prognosis than nonsignet colorectal carcinoma. Usually only palliative surgery is possible. A high incidence of peritoneal seeding and a low incidence of hepatic metastasis is characteristic of signet-ring cell cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF02236218DOI Listing

Publication Analysis

Top Keywords

signet-ring cell
32
cell cancer
28
colorectal carcinoma
16
ordinary colorectal
12
primary colorectal
12
colorectal signet-ring
12
study matched
12
matched age
12
age gender
12
gender grade
12

Similar Publications

Background Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer with significant variations in clinical characteristics and poor prognosis. However, there is limited data available in Pakistan. Therefore, we analyzed to examine the incidence, clinicopathological features, treatments, and outcomes of SRCC in colorectal cancer cases in Pakistan.

View Article and Find Full Text PDF

Survival differences in rare histological prostate cancer (PCa) subtypes relative to age-matched population-based controls are unknown. Within Surveillance, Epidemiology, and End Results database (2004-2020), newly diagnosed (2004-2015) PCa patients were identified. Relying on the Social Security Administration Life Tables (2004-2020) with 5 years of follow-up, age-matched population-based controls (Monte Carlo simulation) were simulated for each patient.

View Article and Find Full Text PDF

Eighty-Nine Cases of Primary Prostatic Signet Ring Cell Carcinoma-Systematic Review.

Clin Genitourin Cancer

November 2024

Department of Urology, Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia; Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.

Signet ring cell adenocarcinoma is a rare subtype of mucinous adenocarcinoma that affects the gastrointestinal tract and the prostate. Prostatic signet ring cell carcinoma comprises 0.02% of all cases of prostate cancer and 0.

View Article and Find Full Text PDF

Background: Signet-ring cell carcinoma (SRCC) originates from undifferentiated stem cells in the neck of glands within the lamina propria of the mucosa. Primarily affecting the stomach, SRCC can also involve the breast, pancreas, gallbladder, colon, and bladder, although these cases are rare. SRCC of the prostate is extremely rare, and diagnosing it pelvic puncture is particularly challenging.

View Article and Find Full Text PDF

A 62-year-old man was diagnosed with Stage Ⅲ signet ring cell carcinoma of the lower thoracic esophagus. The patient underwent 2 courses of neoadjuvant cisplatin and 5-fluorouracil(SP therapy), demonstrating stable efficacy. Subsequently, the patient underwent subtotal esophagectomy with thoracoabdominal 2-field lymphadenectomy via right thoracotomy, followed by esophageal reconstruction using a gastric tube through a retrosternal route.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!